Bev Hope’s Post

Very excited about this collaboration with the PSPP! At Goldenrod Therapeutics, we are developing next-generation, small molecule, oral PDE4B inhibitors for the treatment of severely debilitating diseases that affect the central nervous system and for which current treatments are either inadequate or non-existent. Globally, about 1 in 5 people suffer from chronic pain, an extremely complex and debilitating condition which varies significantly between individuals. Unfortunately, highly addictive opioids are still the most commonly prescribed medications for chronic pain and, despite decades of effort, there are still no exceptional alternatives on the market. Goldenrod's non-opioid small molecule drugs have the potential to change this! Importantly, this partnership marks our second collaboration with an NIH Institutional Program - the first being our acceptance into NIDA's Addiction Treatment Discovery Program (ATDP) in 2022. We are thrilled to work with these key partners, among others, to advance Goldenrod's promising new treatments forward and to address the unmet needs of patients worldwide. #chronicpain #painresearch #paintherapeutics

We are excited to announce that one of our Fannin-founded companies, Goldenrod Therapeutics, has been accepted into the National Institute of Neurological Disorders and Stroke (NINDS) Preclinical Screening Platform for Pain (PSPP). In alignment with the NIH HEAL Initiative, the PSPP is an efficient, rigorous, one-stop screening resource to accelerate discovery of effective, non-addictive, non-opioid pain therapies. The program can assess in vitro and pharmacokinetic profiles, side effect profiles, abuse liability, and efficacy in models relevant to human pain conditions.     Support from the PSPP Program will help accelerate the development of Goldenrod’s small molecule therapeutics towards treating chronic pain, which affects more than 51 million people in the United States alone. We look forward to this partnership and its potential for advancing these promising therapeutics towards the clinic. #Biotech #Neuroscience #Therapeutics #Innovation #Fannin

The moonshot is a fundamental array of new therapeutics. Is monepantel going to be part of this moonshot approach? Can monepantel address one of the underlying mechanism of ALS - dysfunctional autophagy? Follow #PharmAust on its journey to tackle this hideous disease front on. #ALS #ALSStrong #ALSAwareness #MNDAustralia #FightMND #Biotech #Science #Neuroscience #NeurodegenerativeDiseases

🧠 𝗨𝗻𝗰𝗼𝘃𝗲𝗿 𝗻𝗼𝘃𝗲𝗹 𝘁𝗵𝗲𝗿𝗮𝗽𝗲𝘂𝘁𝗶𝗰𝘀 𝗳𝗼𝗿 𝗱𝗲𝗽𝗿𝗲𝘀𝘀𝗶𝗼𝗻 ▶️ https://lnkd.in/gt3rAHuJ In this exciting Inscopix, Inc. webinar, a special guest will unveil the newest findings from a project conducted through the Inscopix Discovery Lab, providing a real-world example of the application of Inscopix miniscope technology to further drug development. In addition, hear more from Dr. Jonathan Nassi on the cutting-edge in vivo imaging assay from the Inscopix Discovery Lab. This innovative approach incorporates miniscope imaging with active behavior to facilitate preclinical pharma studies assessing novel compounds. #depression #neuroscience #Therapeutics #miniscope

At NEURO-SYS, we are a leading preclinical CRO specialized in neurodegenerative diseases such as ALS. Our mission is to support clients in driving groundbreaking research and therapeutic discoveries for these devastating conditions. This ALS Awareness Month, we reaffirm our commitment as a strategic partner empowering biotech and pharmaceutical companies through our scientific expertise and state-of-the-art preclinical capabilities. We pioneer innovative approaches to elucidate disease biology and accelerate the evaluation of promising therapeutic candidates. From study design to execution, our specialized neurodegenerative disease focus enables us to guide clients at every step, applying scientific rigor to keep their programs on the cutting edge. Join us as we fuel pioneering research and discovery efforts to unlock a future free from the burden of ALS and related neurodegenerative diseases. https://lnkd.in/dPKfqquy #LouGehrigsDisease #HopeForACure #FightAgainstALS #ALSAwareness #EndALS #Neuroscience #ALSResearch #DrugDiscovery

𝐋𝐨𝐧𝐳𝐚 𝐚𝐧𝐝 𝐍𝐞𝐮𝐫𝐨𝐒𝐞𝐧𝐬𝐞 𝐓𝐡𝐞𝐫𝐚𝐩𝐞𝐮𝐭𝐢𝐜𝐬 𝐂𝐨𝐥𝐥𝐚𝐛𝐨𝐫𝐚𝐭𝐞 𝐭𝐨 𝐀𝐝𝐯𝐚𝐧𝐜𝐞 𝐀𝐋𝐒 𝐓𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭 Lonza (SIX: LONN) Lonza and NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) NeuroSense Therapeutics announced a collaboration to evaluate biological changes in neurodegenerative diseases, including ALS. This partnership grants NeuroSense access to Lonza's extracellular vesicles expertise. Lonza will develop a method for measuring biomarkers from NDEs to integrate into NeuroSense's lead ALS product, PrimeC. Davide Zocco Davide Zocco, Lonza's Head of Exosomes Development, stated: "Lonza's 'Dev-on-Demand' solution provides NeuroSense with access to expert scientists for their development activities." Alon Ben-Noon Alon Ben-Noon 🇮🇱, NeuroSense's CEO, commented: "This collaboration could be a game-changer for ALS and neurodegeneration. Findings in biomarkers may advance diagnosis and treatment." NeuroSense recently reported positive Phase 2b PARADIGM trial results for PrimeC in ALS, showing a statistically significant slowing of disease progression. #NeurodegenerativeDiseases #ALSResearch #Collaboration #Biotech #Innovation #Biomarkers #Exosomes #Therapeutics #MedicalResearch #Healthcare #Neurology #ClinicalTrials #DrugDevelopment #Lonza #NeuroSense #PrimeC

🌟 𝐈𝐧𝐌𝐞𝐝'𝐬 𝐈𝐍𝐌-𝟗𝟎𝟏: 𝐀 𝐍𝐞𝐰 𝐇𝐨𝐩𝐞 𝐟𝐨𝐫 𝐀𝐥𝐳𝐡𝐞𝐢𝐦𝐞𝐫’𝐬 𝐓𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭! 💡 𝗜𝗻 𝗝𝘂𝗹𝘆 𝟮𝟬𝟮𝟰, InMed Pharmaceuticals recently released preclinical data indicating its proprietary, #smallmolecule compound, INM-901, targets multiple #biological pathways associated with #Alzheimer’sdisease. Among the most interesting data from the recent reports, was the ability of its compound to extend the length of #neurites, which may indicate enhanced neuronal functioning in the #brain and the potential to reverse the #damage caused by Alzheimer’s disease. The company was encouraged with these breakthrough preclinical results and will be advancing the development of the INM-901 Alzheimer’s disease program. InMed's preclinical model of Alzheimer's disease, which is well characterised, showed encouraging outcomes in both in vitro and in vivo trials. The study claims that it might encourage neurite growth and extension, or neutogenesis, a crucial aspect of cell-to-cell communication. In in-vivo experiments, INM-901 also revealed decreased neuroinflammation and improved behaviour, memory, and cognitive function. 𝗕𝗿𝗼𝘄𝘀𝗲 𝗮𝘁 𝗼𝘂𝗿 𝗥𝗲𝗹𝗮𝘁𝗲𝗱 𝗥𝗲𝗽𝗼𝗿𝘁 👉:https://bit.ly/46jbV2x #AlzheimersTreatment #InnovativeTherapy #AlzheimersResearch #MultiFactorialApproach #BreakthroughMedicine #NeuroScience #AlzheimersHope #prophecymarketinsights

🧠 Neuroscience News 🧠 ▪ Brenig Therapeutics - Announced $65m Series A financing to advance leading pre-clinical #ParkinsonsDisease pipeline. Financing was lead by New Enterprise Associates (NEA), with support from existing investors OrbiMed, Torrey Pines Investment LLC, and BGV (BioGeneration Ventures) ▪ Asceneuron SA raises $100m for #Alzheimer’s drug development. The Series C round was led by Novo Holdings, support by additional investors EQT Group, OrbiMed, SR One Capital Management, Sofinnova Partners as well as GSK Equity Investments and the venture arms of Johnson & Johnson and Merck KGaA. ▪ Reunion Neuroscience - announced that the first patient has been dosed in the RECONNECT Phase 2 clinical trial of RE104 for the treatment of postpartum depression (PPD) ▪ Immunic Therapeutics appoint Jason Tardio as Chief Operating Officer and President to lead internal efforts to prepare for the potential launch of vidofludimus calcium (IMU-838), the company's orally available nuclear receptor related 1 (Nurr1) activator for #MultipleSclerosis ▪ Sage Therapeutics and Biogen halt clinical development of SAGE-324 for essential tremor #Neuroscience and #Psychiatry is a focus area of mine where I've had the pleasure of partnering with some amazing companies. If you're looking for new opportunities in the space, looking to grow your team or to talk about market trends, drop me an email - alex.coppen@apsida.com

Exciting news in #neuroscience! According to a recent BioSpace article, the sector's investment surge is catching attention. With $639 million in seed and Series A investments, #neuroscience is second only to #oncology. What's driving this interest? Well, it's a mix of #innovation and regulatory changes. With momentum building, the future looks promising for advancements in neuroscience research and therapies. #Neuroscience #Innovation.

🧠 𝗨𝗻𝗰𝗼𝘃𝗲𝗿 𝗻𝗼𝘃𝗲𝗹 𝘁𝗵𝗲𝗿𝗮𝗽𝗲𝘂𝘁𝗶𝗰𝘀 𝗳𝗼𝗿 𝗱𝗲𝗽𝗿𝗲𝘀𝘀𝗶𝗼𝗻 ▶️ https://lnkd.in/dCmKUnyG In this exciting Inscopix, Inc. webinar, a special guest will unveil the newest findings from a project conducted through the Inscopix Discovery Lab, providing a real-world example of the application of Inscopix miniscope technology to further drug development. In addition, hear more from Dr. Jonathan Nassi on the cutting-edge in vivo imaging assay from the Inscopix Discovery Lab. This innovative approach incorporates miniscope imaging with active behavior to facilitate preclinical pharma studies assessing novel compounds. #depression #neuroscience #Therapeutics #miniscope